Metoclopramide (PrimperanTM) | Launched | D2 antagonist, 5-HT3 antagonist,5-HT4 agonist | Sanofi-Aventis | Nausea-vomiting, GERD, diabetic gastroparesis |
Clebopride (CleborilTM) | Launched | 5-HT4 agonist, 5-HT3 antagonist, D2 antagonist | Almirall | Nausea-vomiting |
Cisapride (PrepulsidTM) | Restricted use | 5-HT4 agonist, 5-HT3 antagonist, 5-HT2 antagonist | Johnson & Johnson | GERD, gastroparesis |
Mosapride (GasmotinTM) | Launched | 5-HT4 agonist, 5-HT3 antagonist | Dainippon-Sumitomo | Gastritis, GERD |
Tegaserod (Zelnorm TM) | Restricted use | 5-HT4 agonist, 5-HT2 antagonist, 5-HT1 agonist, 5-HT3 antagonist | Novartis | IBS, Chronic idiopathic constipatio |
Prucalopride (ResolorTM) | Launched | 5-HT4 agonist | Movetis | Chronic constipation |
M0003, M0004 | Phase II, discontinued | 5-HT4 agonist | Movetis | GERD, gastroparesis |
Renzapride | Phase III, discontinued | 5-HT4 agonist, 5-HT3 antagonist | Alizyme | IBS-C, IBS-M |
E-3620 | PhaseII, discontinued | 5-HT4 agonist, 5-HT3 antagonist | Eisai | GI motility disorders |
Naronapride | Phase II | 5-HT4 agonist | ARYx Therapeutics | Chronic idiopathic constipation, GERD, gastroparesis |
Velusetrag | Phase II | 5-HT4 agonist | Theravance | Chronic constipation, gastroparesis |
TD-8954 | Phase I/II | 5-HT4 agonist | Theravance | Eating disorder |
YKP10811 | Phase II | 5-HT4 agonist | SK biopharm | Chronic constipation, IBS-C |
TD-2749 | Phase I | 5-HT4 agonist | Theravance | GI motility disorders |
AU-228 | Phase I | 5-HT4 agonist | Abbott | GI motility disorders |
DA-6886 | Phase I | 5-HT4 agonist | Dong-A ST | IBS-C |
RQ-10 | Phase I | 5-HT4 agonist | RaQualia | GI motility disorders |
YH-12852 | Phase I | 5-HT4 agonist | Yuhan | IBS-C |